Nuclear PD-L1 has been detected as a poor prognostic marker in breast cancer, lung adenocarcinoma, renal cell carcinoma, hepatocellular carcinoma, and prostate cancer (24–28). The gene discussed is CD274; the disease is prostate cancer.